With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks ...
pharmaphorum3d
Regeneron and Alnylam seek RNAi therapies for NASH
Regeneron and Alnylam are to research treatments ... and is associated with increased risk of problems such as diabetes, heart attacks, and strokes. Drugs that get to market could generate ...
Yahoo Finance23d
Regeneron Reports Eylea Sales, Provides Other Pipeline Updates
Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference. Shares of the company moved up in pre-market trading on Jan. 14 ...
Long Island Press8d
Four Nassau students named Regeneron finalists
Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron ...
Yahoo Finance24d
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Regeneron collaborates with Truveta and leading American health systems to massively extend its DNA-linked healthcare database to further advance scientific innovation and healthcare delivery ...